Early in the development of 3CTN, a Patient Representative Advisory Committee (PRAC) was struck to help the 3CTN CC ensure that PPI is infused into all central and regional 3CTN activities. Accountable to the 3CTN Management Committee, the PRAC is a team of 3CTN Patient Representatives and 3CTN CC staff with the focus of providing feedback, insight, expertise and support to the Network. The PRAC’s deliverables, inside the 3CTN framework for 2018-2022, will be:
- Ensure the infusion of meaningful Patient Representation throughout 3CTN;
- In collaboration with the Canadian Cancer Action Network (CCAN), develop and validate a framework and role description for Patient Representatives within 3CTN;
- Further incorporation of Patient Representatives within the clinical research communities;
- Assist 3CTN with actively soliciting Patient involvement in the development and evaluation of 3CTN activities.
3CTN is in the process of expanding commitee membership. Patient Representative Committee Members demonstrate interest and knowledge of patient representative roles and engagement. At the discretion of Committee members, composition may expand based on opportunities to work with interested stakeholders, other patient reprensentatives, healthcare providers.
If you are interested in joining the Patient Representative Advisory Committee, please contact Suzana.Kovacevicoicr.on.ca (Suzana Kovacevic.)
Fred Clark - Manitoba (Chair)
Gretta Hutton - Ontario
Judy Needham - British Columbia
Louise Gagne - Quebec
Jean Francois - Quebec
Stephen Sundquist (ex officio) - Executive Director, Canadian Cancer Clinical Trials Network
Suzana Kovacevic (ex officio) - Manager, Research Projects, Canadian Cancer Clinical Trials Network